ARIS, April 15 (Reuters) – Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, demanded help to maintain operations in the EU despite threatened U.S. tariffs on imports, including measures to compensate them for the cost of pharmaceutical innovations, French business newspaper Les Echos reported on Tuesday.
In the letter sent to European Commission President Ursula von der Leyen, the companies — including Pfizer (PFE.N), opens new tab, Eli Lilly (LLY.N), opens new tab and AstraZeneca (AZN.L), opens new tab — said they face cost disadvantages in Europe versus the United States, where drugs are sold at prices that on average are twice that of some European countries, such as France, Les Echos reported.
